Imaging cellular pharmacokinetics of 18F-FDG and 6-NBDG uptake by inflammatory and stem cells

Objectives Myocardial infarction (MI) causes significant loss of cardiomyocytes, myocardial tissue damage, and impairment of myocardial function. The inability of cardiomyocytes to proliferate prevents the heart from self-regeneration. The treatment for advanced heart failure following an MI is heart transplantation despite the limited availability of the organs. Thus, stem-cell-based cardiac therapies could ultimately prevent heart failure by repairing injured myocardium that reverses cardiomyocyte loss. However, stem-cell-based therapies lack understanding of the mechanisms behind a successful therapy, including difficulty tracking stem cells to provide information on cell migration, proliferation and differentiation. In this study, we have investigated the interaction between different types of stem and inflammatory cells and cell-targeted imaging molecules, 18F-FDG and 6-NBDG, to identify uptake patterns and pharmacokinetics in vitro. Methods Macrophages (both M1 and M2), human induced pluripotent stem cells (hiPSCs), and human amniotic mesenchymal stem cells (hAMSCs) were incubated with either 18F-FDG or 6-NBDG. Excess radiotracer and fluorescence were removed and a 100 μm-thin CdWO4 scintillator plate was placed on top of the cells for radioluminescence microscopy imaging of 18F-FDG uptake, while no scintillator was needed for fluorescence imaging of 6-NBDG uptake. Light produced following beta decay was imaged with a highly sensitive inverted microscope (LV200, Olympus) and an Electron Multiplying Charge-Couple Device (EM-CCD) camera. Custom-written software was developed in MATLAB for image processing. Results The average cellular activity of 18F-FDG in a single cell of hAMSCs (0.670±0.028 fCi/μm2, P = 0.001) was 20% and 36% higher compared to uptake in hiPSCs (0.540±0.026 fCi/μm2, P = 0.003) and macrophages (0.430±0.023 fCi/μm2, P = 0.002), respectively. hAMSCs exhibited the slowest influx (0.210 min-1) but the fastest efflux (0.327 min-1) rate compared to the other tested cell lines for 18F-FDG. This cell line also has the highest phosphorylation but exhibited the lowest rate of de-phosphorylation. The uptake pattern for 6-NBDG was very different in these three cell lines. The average cellular activity of 6-NBDG in a single cell of macrophages (0.570±0.230 fM/μm2, P = 0.004) was 38% and 14% higher compared to hiPSCs (0.350±0.160 fM/μm2, P = 0.001) and hAMSCs (0.490±0.028 fM/μm2, P = 0.006), respectively. The influx (0.276 min-1), efflux (0.612 min-1), phosphorylation (0.269 min-1), and de-phosphorylation (0.049 min-1) rates were also highest for macrophages compared to the other two tested cell lines. Conclusion hAMSCs were found to be 2–3× more sensitive to 18F-FDG molecule compared to hiPSCs/macrophages. However, macrophages exhibited the most sensitivity towards 6-NBDG. Based on this result, hAMSCs targeted with 18F-FDG could be more suitable for understanding the mechanisms behind successful therapy for treating MI patients by gathering information on cell migration, proliferation and differentiation.

[1]  E. Rulifson,et al.  Paracrine Effects of the Pluripotent Stem Cell-Derived Cardiac Myocytes Salvage the Injured Myocardium , 2017, Circulation research.

[2]  M. McConnell,et al.  Direct evaluation of myocardial viability and stem cell engraftment demonstrates salvage of the injured myocardium. , 2015, Circulation research.

[3]  H. Dai,et al.  Graphite oxide nanoparticles with diameter greater than 20 nm are biocompatible with mouse embryonic stem cells and can be used in a tissue engineering system. , 2014, Small.

[4]  V. Fuster,et al.  2-deoxy-2-[18F]fluoro-d-mannose positron emission tomography imaging in atherosclerosis , 2014, Nature Medicine.

[5]  Lei Xing,et al.  Radioluminescence Microscopy: Measuring the Heterogeneous Uptake of Radiotracers in Single Living Cells , 2012, PloS one.

[6]  Phillip C. Yang,et al.  Bone marrow cell therapy in clinical trials: a review of the literature. , 2012, Reviews on recent clinical trials.

[7]  G. Daley,et al.  The promise and perils of stem cell therapeutics. , 2012, Cell stem cell.

[8]  Kai Yang,et al.  In vivo targeting and imaging of tumor vasculature with radiolabeled, antibody-conjugated nanographene. , 2012, ACS nano.

[9]  Mary G. George,et al.  Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement From the American Heart Association , 2011, Circulation.

[10]  N. Bursac,et al.  Implantation of Mouse Embryonic Stem Cell-Derived Cardiac Progenitor Cells Preserves Function of Infarcted Murine Hearts , 2010, PloS one.

[11]  C. Bearzi,et al.  Human cardiac stem cells: the heart of a truth. , 2009, Circulation.

[12]  P. Menasché Cell-based therapy for heart disease: a clinically oriented perspective. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  Ingo Kutschka,et al.  Multimodal evaluation of in vivo magnetic resonance imaging of myocardial restoration by mouse embryonic stem cells. , 2008, The Journal of thoracic and cardiovascular surgery.

[14]  Ahmad Y. Sheikh,et al.  Multimodality Evaluation of the Viability of Stem Cells Delivered Into Different Zones of Myocardial Infarction , 2008, Circulation. Cardiovascular imaging.

[15]  Lila R Collins,et al.  Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts , 2007, Nature Biotechnology.

[16]  G. Lyons,et al.  Transplanted embryonic stem cells following mouse myocardial infarction inhibit apoptosis and cardiac remodeling. , 2007, American journal of physiology. Heart and circulatory physiology.

[17]  H. Zaidi,et al.  Tracer Kinetic Modeling in PET. , 2007, PET clinics.

[18]  Arjun Deb,et al.  Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair , 2007, Proceedings of the National Academy of Sciences.

[19]  Gerald J Berry,et al.  Dual in vivo magnetic resonance evaluation of magnetically labeled mouse embryonic stem cells and cardiac function at 1.5 t , 2006, Magnetic resonance in medicine.

[20]  C. Murry,et al.  Regenerating the heart , 2005, Nature Biotechnology.

[21]  J. Ingwall,et al.  Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells , 2005, Nature Medicine.

[22]  D. Torella,et al.  Adult Cardiac Stem Cells Are Multipotent and Support Myocardial Regeneration , 2003, Cell.

[23]  C S Patlak,et al.  Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[24]  R. Carson Tracer Kinetic Modeling in PET , 2005 .

[25]  B. Keck,et al.  Thoracic organ transplantation in the US. , 2002, Clinical transplants.